Donald’s responsibilities include a senior role in content development for global value dossiers and AMCP dossiers, as well as project management. He has experience in many therapeutic areas including rare diseases (tuberous sclerosis complex, cystic fibrosis, Fabry disease, Gaucher disease, cystinosis, metachromatic leukodystrophy, IgA pemphigus); oncology (acute myeloid leukemia [AML], glioblastoma multiforme [GBM], melanoma, cutaneous T-cell lymphoma, myeloma, breast cancer, colorectal cancer, prostate cancer, thyroid cancer); microbiology and immunology (bacteriology, virology, vaccinology, antimicrobial agents); neurology (multiple sclerosis); diagnostic imaging (magnetic resonance imaging [MRI]); endocrinology (acromegaly, diabetes, growth hormones); gout; plaque psoriasis; psoriatic arthritis; transplantation (renal); cardiovascular disease (familial hypercholesterolemia, statins, cardiac catheterization, LDL-apheresis, angiography, hypertriglyceridemia, omega-3 fatty acids); autism spectrum disorders (ASDs); attention-deficit hyperactivity disorder (ADHD); women’s health care (hormone therapy); statistics; parenteral nutrition; focal segmental glomerulosclerosis (FSGS); pain (osteoarthritis, post-surgical pain); and, hematology (thrombocytopenia, anticoagulant therapies). In addition, Donald has also worked on projects examining medication adherence (in multiple sclerosis) and health state utilities (in cardiovascular disease). He also has prior experience summarizing HTAs reviews from NICE, CADTH, and SMC.
Prior to working in market access communications, Donald worked in the evidence review and synthesis (ERS) group at Evidera where he acted as a lead researcher and writer on systematic and targeted literature reviews. In addition, he previously worked as a principal medical writer for Custom Learning Designs Inc. Dr. Smith has a PhD in microbiology and molecular genetics from Harvard Medical School and a BS in microbiology from the University of Maine, Orono.